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Background. There are few recent data on the rates of AIDS-defining opportunistic infections (OIs) among human immuno-
deficiency virus (HIV)–infected patients in care in the United States and Canada.
Methods. We studied HIV-infected participants in 16 cohorts in the North American AIDS Cohort Collaboration on Research and
Design (NA-ACCORD) during 2000–2010. After excluding 16 737 (21%) with any AIDS-defining clinical events documented before
NA-ACCORD enrollment, we analyzed incident OIs among the remaining 63 541 persons, most of whom received antiretroviral ther-
apy during the observation. We calculated incidence rates per 100 person-years of observation (hereafter, “person-years”) with 95%
confidence intervals (CIs) for the first occurrence of any OI and select individual OIs during 2000–2003, 2004–2007, and 2008–2010.
Results. A total of 63 541 persons contributed 261 573 person-years, of whom 5836 (9%) developed at least 1 OI. The incidence
rate of any first OI decreased over the 3 observation periods, with 3.0 cases, 2.4 cases, and 1.5 cases per 100 person-years of observation
during 2000–2003, 2004–2007, and 2008–2010, respectively (Ptrend<.001); the rates of most individual OIs decreased as well. During
2008–2010, the leading OIs included Pneumocystis jiroveci pneumonia, esophageal candidiasis, and disseminated Mycobacterium
avium complex or Mycobacterium kansasii infection.
Conclusions. For HIV-infected persons in care during 2000–2010, rates of first OI were relatively low and generally declined over
this time.
Keywords. AIDS-related opportunistic infections; HIV cohort studies; incidence; prophylaxis; combination antiretroviral
therapy; CD4+ T-lymphocyte count; epidemiology.
Despite declines in the incidence of AIDS-defining oppor-
tunistic infections (OIs) following the advent of effective com-
bination antiretroviral therapy (ART) [1–5], OIs remain
prominent causes of hospitalization [6, 7] and death [8–11]
among human immunodeficiency virus (HIV)–infected per-
sons in the United States and other high-income countries.
Concurrent HIV infection and AIDS diagnoses in the United
States are common, with few signs of nationwide improvement
in recent years among individuals who receive a diagnosis
during late-stage disease [12, 13]. OIs continue to be frequently
documented in persons presenting with late-stage HIV disease
and may be the sentinel events prompting initial diagnosis [14–
17]; however, there are few robust recent data on their incidence
rates and types among North American patients in HIV care [3,
4]. The National HIV Surveillance System in the United States
and the HIV and AIDS surveillance maintained by the Public
Health Agency of Canada are deemed no longer suitable for
monitoring OIs rates because of increasing reliance on CD4+
T-cell count criteria alone for classification of AIDS and resul-
tant substantial OI underreporting [18–20].
OIs continue to occur among patients prescribed ART and at
relatively high CD4+ T-cell counts in both European [5, 21–24]
and US [3] cohorts. Their occurrence varies by plasma HIV-1
RNA level [21, 25] and other clinical and demographic factors
[1], which may correlate with level of engagement in HIV care.
Characterizing the key OIs that continue to occur among North
Received 9 October 2015; accepted 24 January 2016; published online 18 April 2016.
Presented in part: Conference on Retroviruses and Opportunistic Infections, Boston, Massa-
chusetts, 3–6 March 2014. Abstract 843.
Correspondence: K. Buchacz, Centers for Disease Control and Prevention, 1600 Clifton Rd NE,
Mailstop E-45, Atlanta, GA 30329 (acu7@cdc.gov).
The Journal of Infectious Diseases® 2016;214:862–72
Published by Oxford University Press for the Infectious Diseases Society of America 2016. This
work is written by (a) US Government employee(s) and is in the public domain in the US.
DOI: 10.1093/infdis/jiw085
862 • JID 2016:214 (15 September) • Buchacz et al
American patients in the contemporary ARTera, and the CD4+ T-
cell counts at which they occur, provides important data for in-
forming opportunistic illness screening, prophylaxis, and manage-
ment guidelines [16, 26], and other aspects of HIV care and
treatment [27] to reduce OI-associated mortality and morbidity
[10,25]. It is of particular interest and epidemiologic value to char-
acterize the rates of first OIs among patients who have no history
of prior AIDS-defining clinical events, not only because such pa-
tients compose a well-defined study population, but also because,
on average, they better represent the leading edge of the HIV ep-
idemic, namely, contemporary patients with more-recent HIV in-
fections and less extensive treatment histories.
In this report, we focus on incident AIDS-defining infections
in the North American AIDS Cohort Collaboration on Research
and Design (NA-ACCORD); rates of AIDS-defining malignan-
cies have been described separately [28]. We sought to assess
whether incidence rates of first OIs have continued to decline
or have stabilized over the last decade among such HIV-infected
patients in care and to describe risk factors for and the epidemi-
ology of these OIs in the recent ART era.
METHODS
Study Population
The NA-ACCORD is the largest collaboration of longitudinal
HIV cohort studies in North America and has compiled data
from >100 clinical sites in the United States and Canada [12,
29]. Briefly, at scheduled intervals, participating HIV cohorts
submit data regarding enrolled participants’ demographic char-
acteristics, vital status, prescribed antiretrovirals, clinical diag-
noses, and dates and results of laboratory tests including HIV
load and CD4+ T-cell count. These clinical data are obtained
from routine chart abstractions or scheduled study visits, de-
pending on the cohort. Among clinical cohorts, only persons
with ≥2 clinical visits within 12 months are enrolled into the
NA-ACCORD. Death is ascertained by each contributing co-
hort by using a variety of methods, including the National
Death Index, the Social Security Death Index, and state, provin-
cial, and local sources, such as death certificates and electronic
medical records. NA-ACCORD data undergo extensive quality
control for completeness and accuracy per a standardized pro-
tocol before they are combined into harmonized data files at
the NA-ACCORD’s Data Management Center (University of
Washington, Seattle, Washington). The data are reviewed again,
organized into analytic files, and analyzed at the NA-ACCORD
Epidemiology and Biostatistics Core (Johns Hopkins Univer-
sity, Baltimore, Maryland). The human subjects research ac-
tivities of the NA-ACCORD and each of the participating
cohort studies have been reviewed and approved by their
respective local institutional review boards and by the Johns
Hopkins School of Medicine.
We analyzed data from HIV-infected persons followed in 16
participating cohorts in NA-ACCORD in the United States and
Canada, listed at the end of the text, during 2000–2010; each
cohort agreed to participate and had available OI data for this
analysis. Because the protocols for collection and validation of
OIs varied across participating cohorts, if a given cohort con-
tributed no OI events of a specific type (eg, cryptococcal men-
ingitis and disseminated coccidioidomycosis) during any one of
the 3 analysis periods (2000–2003, 2004–2007, and 2008–2010),
that cohort was excluded entirely from analyses of that specific
OI during that particular period, to avoid underestimating OI
incidence rates. Sensitivity analyses without this exclusion
were performed (see below). We further restricted analyses to
persons who had no history of any clinical AIDS events at the
start of their observation but imposed no restrictions on their
CD4+ T-cell count, HIV load, or prescription of ART at base-
line. We analyzed data from 1 January 2000 or the date the par-
ticipating cohort began contributing data (cohort entry date),
whichever came later. The start of observation for each patient
(baseline) was the later of the patient’s enrollment date in the
participating cohort or 1 January 2000. The end of follow-up
for each patient was the earliest of the following: the patient’s
last CD4+ T-cell count or last HIV load date plus 6 months,
the date of the event being analyzed (ie, either the first occur-
rence of any OI diagnosis or the first occurrence of a specific OI
of interest, regardless of prior occurrence of other OIs), the date
of death, or the end of the study period (31 December 2010).
We defined 3 calendar periods for analyses: 2000–2003 (early
period), 2004–2007 (middle period), and 2008–2010 (contem-
porary ART period). The participating cohorts relied on stan-
dard definitions for ART and for prophylaxis to prevent
Pneumocystis pneumonia (PCP) and disseminated Mycobacte-
rium avium complex (MAC) infection [26, 27]. We studied all
OIs listed in the Centers for Disease Control (CDC) 2014 sur-
veillance case definition for HIV infection [18, 19, 26], with a
few exceptions, as noted in the Appendix. OI events were de-
fined solely on the basis of diagnoses recorded by the participat-
ing cohorts.
The CD4+ T-cell counts and HIV loads at the beginning of
each period were those measured nearest to the start of obser-
vation in the period (from 6 months before up to 6 months
after). We also examined the CD4+ T-cell count and HIV
load closest to incident OI diagnoses (from 6 months before
up to 3 months after). Finally, the CD4+ T-cell count and
HIV load at ART initiation were the nearest measurements
from 6 months before through the date of ART initiation.
Statistical Methods
We calculated incidence rates of OI diagnoses per 100 person-
years with 95% Poisson confidence intervals (CIs) for the first
occurrence of any OI and for the first occurrence of select OIs
that were uniformly ascertained in the participating cohorts. In-
cidence rate estimates for selected OIs were calculated by ignor-
ing the occurrence of other OIs prior to the first occurrence of
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the OI of interest. For each OI, we summed the total observation
time across participating patients from the start of observation
to the end of follow-up for each patient. The incidence of indi-
vidual OIs was estimated on an event-by-event basis. For exam-
ple, in the analyses of incident tuberculosis, if during follow-up
a person received a diagnosis of another OI, such as candidiasis,
before receiving a diagnosis of tuberculosis, they still contribut-
ed all available observation time up to the date of tuberculosis
diagnosis to the tuberculosis incidence rate calculation. Tests of
temporal trends in OI rates were assessed using Poisson regres-
sion models.
We also quantified the incidence rates of any OI in a subset of
persons who initiated ART during 2000–2010. We estimated
the time to any first OI with the Kaplan–Meier method; as a
sensitivity analysis, we accounted for the competing risk of
death [30, 31], thus providing an overall estimate of the cumu-
lative incidence of the OI event occurring prior to death accord-
ing to calendar period or CD4+ T-cell count at ART initiation.
Using Poisson regression, we further explored the clinical and
sociodemographic risk factors for select high-incidence OIs, ad-
justing for the following factors at the start of observation in
each calendar period: age, sex, race/ethnicity, CD4+ T-cell
count, HIV load, and cohort. A patient may have contributed
observation time to multiple calendar periods. We explored ad-
ditional modeling strategies by including a variable for whether
or not a patient used ART at the start of observation for each
calendar period, but we omitted this variable from the final
models because of its strong dependence on CD4+ T-cell
count at the start of the period and calendar period. We report
incidence rate ratios (IRRs) and 95% CIs. We performed anal-
yses using SAS, version 9.3 (Cary, North Carolina).
RESULTS
We identified 80 278 HIV-infected persons followed in 16 par-
ticipating cohorts in NA-ACCORD in the United States and
Canada during 2000–2010. After excluding 16 737 persons
(21%) with any history of documented AIDS-defining condi-
tions at baseline (see the Appendix for details), we analyzed in-
cident OIs among the remaining 63 541 persons, regardless of
their baseline immunologic status or ART use.
Persons at Risk for Development of OIs
Of persons studied, median age at baseline was 40 years (inter-
quartile range, 34–47 years), 78% were men, 40% were white,
37% were black, 41% were men who have sex with men
(MSM), 19% were persons who had injection drug use (IDU)
as an HIV risk factor; and 12% were Canadian (Table 1). Medi-
an CD4+ T-cell count at baseline was 360 cells/mm3 (IQR, 196–
557 cells/mm3), about one third had a baseline HIV load of
<500 copies/mL, and 43% had any documented ART prescrip-
tion at the start of observation for this analysis. The subset of
persons who were antiretroviral naive at baseline and initiated
ART sometime during their observation had largely similar de-
mographic characteristics to those of all persons in our study
population (Table 1).
During 2000–2010, 63 541 persons contributed 261 573 per-
son-years of observation, and 5836 developed at least 1 OI. The
27 500 persons who started ART during the period of analysis
Table 1. Baseline Characteristics of Patients at Risk of Incident
Opportunistic Infections, NA-ACCORD, 2000–2010, United States and
Canada
Characteristic
All Persons at Risk
(n = 63 541)
Persons Starting ART
(n = 27 500)
Age, y
<35 18 202 (29) 8208 (30)
35–44 24 863 (39) 10 254 (37)
≥45 20 476 (32) 9038 (33)
Median (IQR) 40 (34–47) 40 (33–47)
Sex
Male 49 483 (78) 21 363 (78)
Female 14 058 (22) 6137 (22)
Race/ethnicity
White 25 354 (40) 9930 (36)
Black/African American 23 248 (37) 10 207 (37)
Hispanic/Latino 8880 (14) 4064 (15)
Other 2927 (5) 1378 (5)
Missing 3132 (5) 1921 (7)
HIV risk group
MSM 26 289 (41) 11 285 (41)
IDU 11 803 (19) 4485 (16)
Heterosexual 16 440 (26) 7733 (28)
Other/unknown 9009 (14) 3997 (15)
Country of cohort
US 56 131 (88) 23 235 (84)
Canada 7410 (12) 4265 (16)
CD4+ T-cell count, cells/mm3a
<200 15 434 (24) 9978 (36)
200–349 13 907 (22) 8642 (31)
350–499 12 310 (19) 4219 (15)
500+ 18 932 (30) 3478 (13)
Missing 2958 (5) 1183 (4)
Median (Q1, Q3) 360 (196–557) 252 (134–376)
HIV load, copies/mLa
<500 19 619 (31) 3941 (14)
500–9999 11 984 (19) 3573 (13)
10 000–99 999 17 251 (27) 9569 (35)
≥100 000 11 092 (17) 8046 (29)
Missing 3595 (6) 2371 (9)
Median (IQR) 7485 (200–61 787) 41 576 (5300–122 576)
Ever used ART at start of observation
Yes 27 310 (43) NA
No 36 231 (57) NA
Data are no. (%) of patients, unless otherwise indicated. Baseline was defined as the later of
the patient’s enrollment date in the participating cohort or 1 January 2000.
Abbreviations: ART, combination antiretroviral therapy; HIV, human immunodeficiency virus;
IDU, persons who inject drugs; IQR, interquartile; MSM, men who have sex with men; NA,
not applicable.
a CD4+ T-cell count and HIV load measurements were as follows: for all persons at risk, nearest
measurement to baseline date from 6 months before to 6 months after; for persons starting
ART, nearest measurement within 6 months before or on the date of ART start.
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contributed 107 875 person-years of observation, and 1843 de-
veloped at least 1 OI.
Trends in Rates of OIs
The incidence rates of the first OI decreased over time, with val-
ues of 2.96 events/100 person-years for 2000–2003, 2.36 events/
100 person-years for 2004–2007, and 1.45 events/100 person-
years for 2008–2010 (P < .001, by the test for trend; Table 2).
These decreases coincided with temporal improvements in clin-
ical status and care of the entire study population: increases in
the percentage of observation time during which ART was re-
ceived, median CD4+ T-cell counts, and frequency with HIV
loads of <500 copies/mL (P < .001 for comparisons; Table 2).
The incidence rates of key high-frequency OIs declined signifi-
cantly over time (P < .05; Figure 1), as did the rates of most
other OIs (Table 3), except for the less-frequent OIs, such as
isosporiasis, coccidioidomycosis, and histoplasmosis, as well
as toxoplasmosis and CMV infection, for which no significant
declines were noted (P≥ .05). During 2008–2010, the leading
OIs included PCP, esophageal candidiasis, and disseminated
MAC or M. kansasii infection.
In sensitivity analyses of OI incidence rates that included per-
son-years of observation for cohorts that did not report any OIs
of a given type during the calendar period(s), we found some-
what lower rates for some OIs (Supplementary Table 1), but the
overall first OI rates and the statistical inferences regarding tem-
poral trends were similar.
Risk Factors for OIs
In multivariable Poisson regression models (Supplementary
Table 2) that included variables for age, sex, race, HIV risk
category, CD4+ T-cell count, and HIV load at the start of the
calendar period, and the calendar period, factors independently
(P < .05) associated with occurrence of any first incident OI in-
cluded African American/black race or Hispanic/Latino ethnic-
ity (IRR, 1.11 and 1.12, respectively, compared with white), IDU
and heterosexual HIV transmission risk group (IRR, 1.21 and
1.15, respectively, compared with MSM), lower CD4+ T-cell
count categories (IRRs of 5.17 and 1.65, respectively, for CD4+
T-cell counts of <200 and 200–349 cells/mm3, compared with
≥500 cells/mm3), higher HIV load (IRR, 1.50 per 1 log10 copies/
mL), and later calendar periods (IRR, 0.94 and 0.68, respectively
for 2004–2007 and 2008–2010, compared with 2000–2003). For
most individual OIs, the incidence rates were consistently and
markedly increased among persons with low CD4+ T-cell
counts and elevated HIV loads, and some associations with
sex, race/ethnicity, and HIV risk status were noted (Supplemen-
tary Table 2).
Occurrence of OIs Among Persons Starting ART
Among a subset of persons initiating ART, the incidence rate of
any first OI declined over the 3 calendar periods (Table 2) in a
similar pattern as for all persons studied. Overall, by 2 years
after initiating ART, approximately 4% of persons experienced a
first OI, and that percentage was 3% for persons starting ART in
Table 2. Incidence Rates and Other Descriptive Information for Patients Followed for Incident AIDS-Defining Opportunistic Infections (OIs) Overall and
During 3 Observation Periods, NA-ACCORD, 2000–2010, United Sates and Canada
Variable Overall 2000–2003 2004–2007 2008–2010
Unique persons contributing observation time, no. 63 541 34 497 40 567 39 316
Person-years, no. 261 573 80 031 102 281 79 260
Any first OI
Events, no. 5836 2329 2368 1139
Incidencea (95% CI) 2.27 (2.21–2.33) 2.96 (2.84–3.08) 2.36 (2.27–2.46) 1.45 (1.37–1.54)
Death at any time
Events, no. 1076 427 382 267
Incidencea (95% CI) 0.41 (0.39–0.44) 0.54 (0.49–0.59) 0.38 (0.34–0.42) 0.34 (0.30–0.38)
Any first OI among persons initiating ART
Events, no. 1843 519 826 498
Incidencea,b (95% CI) 2.01 (1.92–2.10) 3.24 (2.97–3.53) 2.21 (2.07–2.37) 1.29 (1.19–1.41)
Person-years during which ART was received, % of total 82 79 81 86
CD4+ T-cell count, cells/mm3
Midpoint of the observation period, median 417 400 419 466
Entire observation period, mean of means 440 433 446 492
HIV load measurements <500 copies/mL, % of total
Midpoint of the observation period 58 51 57 73
Entire observation period, mean 69 67 74 83
Analysis entry (baseline) date is the later of the patient’s enrollment date in NA-ACCORD or 1 January 2000.
Abbreviations: ART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus.
a Incidence data denote the number of events per 100 person-years of observation. The start of observation for incidence calculations in a given period is the later of the beginning date for that
period or the patient’s start of observation in that period if patient is still OI free. The end of observation for incidence calculations is the first of the following dates: death date, OI diagnosis date,
last CD4+ T-cell count or HIV load measurement plus 6 months, and 31 December 2010. If OI cases for any participating cohort over the whole calendar period numbered 0, that given cohort
was dropped from the analysis for that particular OI in that period. See Supplementary Table 1 for results without such cohort exclusions.
b Calculated after the start of ART only.
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2008–2010, compared with 5% for those starting ART in 2000–
2003 (Figure 2A). Furthermore, the incidence rate of any first
OI was highly elevated among persons starting ART with CD4+
T-cell counts of <200 cells/mm3, compared with others (Fig-
ure 2B). In subset analyses for persons who started ART in
2008–2010, the 2-year probabilities of developing a first OI were
7.2%, 1.2%, 1.0%, and 1.0% when the CD4+ T-cell count at the
start of ART was <200, 200–349, 350–499, and ≥500 cells/mm3,
respectively. In further analyses incorporating competing risk of
death, the results were similar (Supplementary Figure 1).
Trends in CD4+ T-Cell Counts at OI Diagnosis
The CD4+ T-cell count was available for 5465 of 5836 OI diag-
noses (94%) and was measured a median of 2 days before the OI
diagnosis (IQR, 18 days before to 7 days after the OI diagnosis). A
substantial percentage of OIs occurred among patients with
CD4+ T-cell counts of≥200 cells/mm3: 34% (705 of 2055) during
2000–2003, 34% (755 of 2243) during 2004–2007, and 42% (486
of 1167) during 2008–2010 (P < .001, by the univariate test for
trend). The corresponding median CD4+ T-cell counts at OI di-
agnosis, by calendar period of diagnosis, were 101, 101, and 145
cells/mm3, respectively. The increase in median CD4+ T-cell
count for OI cases corresponded with an increase in the median
CD4+ T-cell count of the entire at-risk population (Table 2).
The median CD4+ T-cell count was above or close to
200 cells/mm3 for tuberculosis and isosporiasis and was
<100 cells/mm3 for most other OIs, including candidiasis,
PCP, CMV infection, and MAC infection (Figure 3). The
range of CD4+ T-cell counts (defined as the 5th–95th percen-
tile) at diagnosis was wide for many OIs. Most persons who
had OIs documented at relatively high CD4+ T-cell counts
also had a high CD4+ T-cell percentage measurement (data
not shown). Notably, most OIs occurred among persons
prescribed ART, a substantial fraction of whom had virological
suppression (<500 copies/mL) proximal to OI diagnosis
(Figure 3). Although it is possible that some of these events
were consistent with immune reconstitution inflammatory syn-
drome [32, 33], we observed no marked increase in risk of any
first OI diagnosis within 6 months of ART initiation (Figure 2A).
DISCUSSION
In our large and demographically diverse cohort of HIV-infected
persons in care in the United States and Canada, we observed
persistent reductions in incidence rates of first OIs during
2000–2010, which coincided with the improvements in viral
suppression and immune status of our study population receiv-
ing increasingly potent and tolerable newer ART regimens [12].
We found that, on average, among contemporary North Amer-
ican patients with no history of an AIDS-defining event, fewer
than 2 in 100 developed any OI per year. Among a subset of
persons starting ART during 2008–2010, the probability of de-
veloping a new OI within the next 2 years was about 7% when
the initial CD4+ T-cell count was <200 cells/mm3 and 1% when
the initial CD4+ T-cell count was ≥500 cells/mm3.
Although direct comparisons of our observed OI rates to
those reported from other cohorts are not appropriate because
Figure 1. The incidence of select opportunistic infections among all 63 541 patients, NA-ACCORD, 2000–2010, United States and Canada. Abbreviations: MAC, Mycobac-
terium avium complex; M. kansasii, Mycobacterium kansasii.
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Table 3. Incidence Rates of Select AIDS-Defining Opportunistic Infections (OIs) Overall and During 3 Observation Periods, NA-ACCORD, United States and
Canada, 2000–2010
OI Diagnosis, Variablea
Observation Period
Overall 2000–2003 2004–2007 2008–2010 P Value
Pneumocystis pneumonia
Events 1828 733 786 309
Person-years 260 278 79 609 101 601 79 068
Incidence (95% CI) 0.70 (.67–.74) 0.92 (.86–.99) 0.77 (.72–.83) 0.39 (.35–.44) <.0001
Candidiasis
Events 1348 466 625 257
Person-years 260 672 79 787 101 795 79 090
Incidence (95% CI) 0.52 (.49–.55) 0.58 (.53–.64) 0.61 (.57–.66) 0.32 (.29–.37) <.0001
Candidiasis, esophageal
Events 1163 403 547 213
Person-years 208 913 63 142 82 284 63 487
Incidence (95% CI) 0.56 (.53–.59) 0.64 (.58–.70) 0.66 (.61–.72) 0.34 (.29–.38) <.0001
M. avium complex or M. kansasii infection
Events 669 251 293 125
Person-years 234 188 70 054 91 614 72 520
Incidence (95% CI) 0.29 (.26–.31) 0.36 (.32–.41) 0.32 (.29–.36) 0.17 (.14–.21) <.0001
CMV infection
Events 631 202 249 180
Person-years 261 281 79 950 102 138 79 194
Incidence (95% CI) 0.24 (.22–.26) 0.25 (.22–.29) 0.24 (.22–.28) 0.23 (.20–.26) .3023
CMV retinitis
Events 156 70 55 31
Person-years 205 053 61 098 80 375 63 580
Incidence (95% CI) 0.08 (.07–.09) 0.11 (.09–.14) 0.07 (.05–.09) 0.05 (.03–.07) <.0001
Tuberculosis, any
Events 624 222 290 112
Person-years 261 070 79 874 102 007 79 189
Incidence (95% CI) 0.24 (.22–.26) 0.28 (.24–.32) 0.28 (.25–.32) 0.14 (.12–.17) <.0001
Tuberculosis, pulmonary
Events 339 121 162 56
Person-years 211 046 63 352 83 465 64 229
Incidence (95% CI) 0.16 (.14–.18) 0.19 (.16–.23) 0.19 (.17–.23) 0.09 (.07–.11) <.0001
Toxoplasmosis
Events 340 103 141 96
Person-years 251 709 76 441 97 746 77 523
Incidence (95% CI) 0.14 (.12–.15) 0.13 (.11–.16) 0.14 (.12–.17) 0.12 (.10–.15) .5487
Cryptococcosis
Events 285 143 106 36
Person-years 261 378 79 967 102 180 79 231
Incidence (95% CI) 0.11 (.1–.12) 0.18 (.15–.21) 0.10 (.09–.13) 0.05 (.03–.06) <.0001
Cryptococcal meningitis
Events 202 101 77 24
Person-years 208 665 63 223 82 501 62 942
Incidence (95% CI) 0.10 (.08–.11) 0.16 (.13–.19) 0.09 (.07–.12) 0.04 (.03–.06) <.0001
Cryptosporidiosisb
Events 185 83 66 36
Person-years 224 649 66 552 87 246 70 850
Incidence (95% CI) 0.08 (.07–.10) 0.12 (.10–.15) 0.08 (.06–.10) 0.05 (.04–.07) <.0001
Histoplasmosisc
Events 159 38 71 50
Person-years 252 914 77 839 99 117 75 959
Incidence (95% CI) 0.06 (.05–.07) 0.05 (.04–.07) 0.07 (.06–.09) 0.07 (.05–.09) .1598
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of multiple cross-cohort differences, including degree of immu-
nosuppression and differences in analytic methods, our abso-
lute OI incidence rates were generally of the same magnitude
as in other studies of OIs during the ART era [3–5]. Higher
HIV loads and lower CD4+ T-cell counts remained associated
with OIs among patients, corroborating earlier analyses [1, 21,
24, 34]. Since most persons in our analyses were ART recipients,
these findings could reflect patients with more-recent ART ini-
tiation, suboptimal responses to ART, or medication nonadher-
ence. In addition, as in prior studies, we found that certain
demographic factors increased the risk for specific OIs [3, 5,
35, 36], including older age, male sex, and HIV transmission
risk behavior (eg, IDU and male-male sex for a variety of oppor-
tunistic infections [5, 35]).
A considerable variability in CD4+ T-cell counts at diagnosis
of OIs has been documented before and after introduction of
ART, with some patients experiencing OIs at relatively high
CD4+ T-cell counts [3, 5, 24]. Two principal hypotheses exist
to explain observed trends [1, 37, 38]. First, the increase in me-
dian CD4+ T-cell count at diagnosis, for the few OI events that
still occur, likely reflects the increased CD4+ T-cell counts of the
entire NA-ACCORD population followed after introduction of
ART (Table 1). Second, ART-associated immune restoration is
functionally incomplete, particularly among persons who had
experienced profound CD4+ T-cell depletion, resulting in OI
occurrence at higher CD4+ T-cell counts.
In this analysis, we investigated incidence rates for the first
occurrence of any OI and of individual OIs. It is difficult to ac-
curately assess the prevalence or total burden of OIs in a pop-
ulation at any point in time, for at least 2 reasons: (1) some viral
OIs are chronic, and their historical documentation since the
date of initial onset is likely incompletely recorded across
many participating cohorts in NA-ACCORD; and (2) some
OIs may occur more than once, and the dates of their onset, res-
olution, and recurrence may not be well recorded. Our approach
to focus on first incident OIs among patients without any
Table 3 continued.
OI Diagnosis, Variablea
Observation Period
Overall 2000–2003 2004–2007 2008–2010 P Value
PML
Events 143 59 57 27
Person-years 234 895 70 217 91 695 72 983
Incidence (95% CI) 0.06 (.05–.07) 0.08 (.07–.11) 0.06 (.05–.08) 0.04 (.03–.05) .0003
Coccidioidomycosisc
Events 31 10 12 9
Person-years 163 657 52 090 63 891) 47 675
Incidence (95% CI) 0.02 (.01–.03) 0.02 (.01–.04) 0.02 (.01–.03) 0.02 (.01–.04) .9700
Isosporiasisb
Events 11 5 4 2
Person-years 135 421 42 342 53 811 39 267
Incidence (95% CI) 0.01 (0–.01) 0.01 (0–.03) 0.01 (0–.02) 0.01 (0–.02) .2950
Any first OId
Events 5836 2329 2368 1139
Person-years 257 466 78 708 100 172 78 586
Incidence (95% CI) 2.27 (2.21–2.33) 2.96 (2.84–3.08) 2.36 (2.27–2.46) 1.45 (1.37–1.54) <.0001
Death
Before first OI
Events 1055 419 374 262
Person-years 261 573 80 031 102 281 79 260
Incidence (95% CI) 0.40 (.38–.43) 0.52 (.48–.58) 0.37 (.33–.4) 0.33 (.29–.37) <.0001
Any time
Events 1076 427 382 267
Person-years 260 195 79 399 101 641 79 155
Incidence (95% CI) 0.41 (.39–.44) 0.54 (.49–.59) 0.38 (.34–.42) 0.34 (.30–.38) <.0001
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; M. avium complex, Mycobacterium avium complex; M. kansasii, Mycobacterium kansasii; PML, progressive multifocal
leukoencephalopathy.
a Person-years data denote the number of person-years of observation. Incidence data denote the number of events per 100 person-years of observation. If the number of individual OI events
reported over the whole calendar period was 0 for a participating cohort, that cohort was dropped from the analysis (numerator and denominator) for that particular OI for that period, to guard
against underestimates of OI rates due to nonascertainment. See Supplementary Table 1 for results without such cohort exclusions.
b Chronic intestinal.
c Disseminated or extrapulmonary.
d Excluding recurrent pneumonia, Salmonella septicemia, and herpes simplex.
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preexisting OIs (ie, no clinical AIDS) as per their available med-
ical history results in our study population being, on average,
more reflective of patients with less advanced HIV disease
and more-recently diagnosed HIV infection; we also examined
OI rates among persons newly starting ART.
Our study has several limitations. We relied on the standardized
study protocols of 16 participating cohorts for ascertaining OIs
without reviewing original medical records to conduct centralized
NA-ACCORD event validation. Although most OIs present acute-
ly and thereby bring affected patients into clinical care, some OIs
might have gone undetected because of presentation and care pro-
vided outside of the participating NA-ACCORD facilities or sub-
clinical presentation or incomplete screening (eg, tuberculosis); we
do not suspect this possible underascertainment to differ over
time, but it could result in underestimation of OI incidence. To
guard against underreporting bias, for each analysis period we ex-
cluded from incidence calculations any cohort reporting no OI
events of that type in the period (eg, this occurred when a cohort
could report all candidiasis cases without differentiating esophage-
al candidiasis); we chose this approach because we believed that
underascertainment of OIs posed a greater threat to the validity
of our results than potentially inflating OI rates (by removing ob-
servation time when no events were recorded). In sensitivity anal-
yses, which considered all available person-time whether or not a
cohort reported any OI events of a given type, the individual OI
rates were somewhat lower, but the inferences regarding decreasing
or level trends in incidence of OIs over time were similar (Supple-
mentary Table 1). Overestimation of first OI incidence rates could
have also resulted from inadvertent inclusion of patients with pre-
existing OI histories that were not documented in available medical
records and because some patients may have had latent infections
or bacterial colonization, as well as immune-compromising condi-
tions beyond HIV infection, that could lead to OI misdiagnoses
[39]. Conversely, our report excludes some OIs, chiefly recurrent
bacterial pneumonia, because neither recurrence nor differentia-
tion between bacterial and viral pneumonia was systematically
documented in most cohorts; thus, our overall incidence rate of
any first OI may be lower than had these diagnoses been included.
We assessed temporal trends and use of ART in a descriptive, eco-
logical fashion and did not quantify the precise reductions in inci-
dence of given OIs attributable to ART use, which was not the
primary goal of our analysis and would have required accounting
for confounding by indication [40]. Finally, ascertainment of ART
prescriptions, particularly before and at enrollment into participat-
ing NA-ACCORD cohorts, may be incomplete, depending on the
available patient medical records.
In conclusion, in our large and diverse cohort of HIV-infected
patients in North America, rates of first OIs in the ART era have
Figure 2. Time from initiation of antiretroviral therapy (ART) to the first incident opportunistic infection, NA-ACCORD, 2000–2010, United States and Canada, by period of
ART initiation (A) and CD4+ T-cell count at the start of ART (B). Analyses do not consider competing risk of death.
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continued to decline during 2000–2010. OIs that predominated
in the pre-ART period in prior US-based analyses [1, 4, 35], such
as PCP and esophageal candidiasis, have remained prominent
in the contemporary ART period. A significant minority of pa-
tients have OIs diagnosed at higher-than-expected CD4+ T-cell
counts and possibly while experiencing virological suppression,
highlighting that healthcare providers need to remain vigilant
for incident opportunistic illnesses in all HIV-infected patients
and reduce OI-associated morbidity and mortality. Early HIV
diagnosis and prompt linkage of HIV-infected patients to care
with immediate offer of ART [27, 41] are also key to achieve fur-
ther gains in OI prevention.
NA-ACCORD COLLABORATING COHORTS
NA-ACCORD collaborating cohorts (and investigators) are as
follows: AIDS Link to the IntraVenous Experience (Gregory
D. Kirk); Adult AIDS Clinical Trials Group Longitudinal Linked
Randomized Trials (included in this analysis; Constance
A. Benson and Ronald J. Bosch); Fenway Health HIV Cohort (in-
cluded in this analysis; Stephen Boswell, Kenneth H. Mayer, and
Chris Grasso); HAART Observational Medical Evaluation and
Research (Robert S. Hogg, P. Richard Harrigan, Julio SG Monta-
ner, Angela Cescon, and Hasina Samji); HIV Outpatient Study
(included in this analysis; John T. Brooks and Kate Buchacz);
HIV Research Network (included in this analysis; Kelly
A. Gebo and Richard D. Moore); Johns Hopkins HIV Clinical
Cohort (included in this analysis; Richard D. Moore); John
T. Carey Special Immunology Unit Patient Care and Research
Database, CaseWestern Reserve University (Benigno Rodriguez);
Kaiser Permanente Mid-Atlantic States (included in this analysis;
Michael A. Horberg); Kaiser Permanente Northern California
(included in this analysis; Michael J. Silverberg); Longitudinal
Study of Ocular Complications of AIDS (included in this analy-
sis; Jennifer E. Thorne); Multicenter Hemophilia Cohort Study–
II (James J. Goedert); Multicenter AIDS Cohort Study (Lisa
P. Jacobson and Gypsyamber D’Souza); Montreal Chest Institute
Immunodeficiency Service Cohort (Marina B. Klein); Ontario
HIV Treatment Network Cohort Study (included in this analysis;
Sean B. Rourke, Ann N. Burchell, and Anita R. Rachlis); Retrovi-
rus Research Center, Bayamon Puerto Rico (Robert F. Hunter-
Mellado and Angel M. Mayor); Southern Alberta Clinic Cohort
(included in this analysis; M. John Gill); Studies of the Conse-
quences of the Protease Inhibitor Era (included in this analysis;
Steven G. Deeks and Jeffrey N. Martin); Study to Understand the
Natural History of HIV/AIDS in the Era of Effective Therapy (in-
cluded in this analysis; Pragna Patel and John T. Brooks); Univer-
sity of Alabama at Birmingham 1917 Clinic Cohort (included in
this analysis; Michael S. Saag, Michael J. Mugavero, and James
Willig); University of North Carolina at Chapel Hill HIV Clinic
Cohort (included in this analysis; Joseph J. Eron and Sonia Nap-
ravnik); University of Washington HIV Cohort (included in this
analysis; Mari M. Kitahata, Heidi M. Crane, and Daniel
R. Drozd); Vanderbilt Comprehensive Care Clinic HIV Cohort
(Timothy R. Sterling, Peter F. Rebeiro, David Haas, Sally Bebawy,
and Megan Turner); Veterans Aging Cohort Study (included in
this analysis; Amy C. Justice, Robert Dubrow, and David Fiellin);
andWomen’s Interagency HIV Study (Stephen J. Gange and Ka-
thryn Anastos).
Figure 3. CD4+ T-cell counts, viral load data, and history of antiretroviral therapy (ART) use among 5836 patients experiencing any first opportunistic infections (OIs), NA-
ACCORD, 2000–2010, United States and Canada. Abbreviations: CADE, candidiasis, esophageal; CAND, candidiasis; CMV, cytomegalovirus; CMVR, CMV retinitis; COC, coc-
cidioidomycosis; CRY, cryptosporidiosis; CRYM, cryptococcal meningitis; HIST, histoplasmosis disseminated; HIV, human immunodeficiency virus; ISO, isosporiasis, chronic
intestinal; MAC, Mycobacterium avium complex or Mycobacterium kansasii infection, disseminated; PCP, Pneumocystis jiroveci pneumonia; PML, progressive multifocal leu-
koencephalopathy; TB, tuberculosis; TBP, tuberculosis, pulmonary; TOX, toxoplasmosis.
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Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
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APPENDIX
AIDS-Defining Opportunistic Infections (OIs) Included and Excluded
From Analyses
The OI diagnoses included in the analyses of the incidence of
any first OI are as follows: Pneumocystis pneumonia (PCP); can-
didiasis; candidiasis, esophageal; Mycobacterium avium complex
or M. kansasii infection, disseminated or extrapulmonary; cyto-
megalovirus (CMV) infection; CMV retinitis; tuberculosis, any;
tuberculosis, pulmonary; toxoplasmosis; cryptococcosis; crypto-
coccal meningitis; cryptosporidiosis, chronic intestinal; histoplas-
mosis, disseminated or extrapulmonary; progressive multifocal
leukoencephalopathy; coccidioidomycosis, disseminated or
extrapulmonary; and isosporiasis, chronic intestinal.
Notably, we excluded the following 3 OI diagnoses: recurrent
bacterial pneumonia, because we were unable to distinguish
viral from bacterial pneumonia in most cases; recurrent Salmo-
nella septicemia, because recurrence versus treatment failure
was not systematically documented; and herpes simplex virus
(HSV) disease, because in most cohorts HSV-related illness
was not systematically documented as chronic ulcers, bronchi-
tis, pneumonitis, or esophagitis. As aforementioned, our analy-
sis excluded all AIDS-defining cancers. Two AIDS-defining
conditions were also omitted: HIV encephalopathy, because it
had no clear infectious etiology beyond HIV itself; and HIV
wasting, because it lacked specificity and systematic corroborat-
ing information in our database (eg, information on weight loss
not available in most participating cohorts).
Among 16 737 persons who were excluded from analyses of
incidence rates of any first OI event because they had a his-
tory of any documented AIDS-defining condition at baseline,
13 807 were excluded for having at least 1 OI event of interest
in this study, and the remaining 2930 were excluded chiefly on
account of AIDS-defining malignancies. In descending order of
frequency, we excluded 6584 cases of PCP, 2692 cases of candi-
diasis (mostly esophageal), 1725 cases of CMV infection, and
1591 cases of disseminated or extrapulmonary M. avium com-
plex orM. kansasii infection, and 1193 cases of tuberculosis; the
remaining OI events each numbered <850.
These prior OI events were diagnosed either before or after
patients’ enrollment into the HIV cohorts participating in
NA-ACCORD; some events were abstracted from historical re-
cords, if available. Of 16 737 OI diagnoses, about 60% were
made in the 1990s, well before inception of NA-ACCORD. Be-
cause we had no data to inform denominators (ie, patients in
follow-up at the participating sites at the time) and because
we suspect incomplete counts for numerators (historic OI
cases), we focused on analyzing incident OI rates and did not
analyze the prevalence of OIs.
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